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oRIGINAL ARTICLE
Introduction: The objective of this study is to report the impact of 
computed tomography (CT) screening on the use of Video-Assisted 
Thoracic Surgery (VATS) in a randomized screening trial.
Methods: The Danish Lung Cancer Screening Trial is a randomized 
clinically controlled trial of 4104 smokers and previous smokers who 
were randomized to either screening with five annual low-dose CT 
scans or no screening in Copenhagen from 2004 to 2006. The major 
end point is the effect of CT screening on lung cancer mortality and 
treatment options. All diagnostic and treatment interventions in both 
groups were monitored prospectively until 1 to 3 years after the last 
screening round.
Results: By February 1, 2011 68 cases of lung cancer were detected 
in the screening group. Furthermore, seven patients with a benign 
nodule underwent surgical treatment because of suspicion of malig-
nancy (12%). Fifty-one of the 68 lung cancer patients were eligible 
for surgical treatment. Eight patients had open thoracotomy. of the 
operations for lung cancer, 84% were performed by VATS in the 
CT-screened arm, significantly higher than the control arm (p < 0.05). 
Thirty-six patients had a VATS lobectomy. one patient had a VATS 
segmentectomy, and four patients had a VATS wedge resection. The 
seven benign nodules were all treated with VATS.
Conclusions: CT screening seems to facilitate the use of VATS in the 
treatment of lung cancer with an 84% rate in our data. Furthermore, 
all benign nodules could be removed by VATS. In our view, a basic 
requirement for a surgical institution to be involved in lung cancer 
CT screening is a dedicated VATS program.
Key Words: Lung cancer, CT, VATS lobectomy, Screening, 
Randomized clinical trial.
(J Thorac Oncol. 2012;7: 1026–1031)
The primary objective of lung cancer screening with low-dose computed tomography (CT) is to detect early-stage 
lung cancer, thereby hopefully improving overall survival. 
A recent report from the National Lung Screening trial sup-
ports this hypothesis with a significant 20% reduction in lung 
cancer mortality among those screened with low-dose spi-
ral CT compared to chest radiograph.1 Minimally invasive 
thoracic surgery or video-assisted thoracic surgery (VATS) 
has evolved during the last two decades, and proved to have 
potential benefits compared to traditional thoracotomy in 
early-stage lung cancer. Several publications have demon-
strated the safety and oncologic efficacy of VATS lobectomy 
in early-stage lung cancer.2–4 Advantages reported for VATS 
lobectomy include reduced perioperative pain,5–7 shorter hos-
pital stay,8 more rapid resumption of normal daily activities,8 
less impairment in pulmonary function postoperatively,6,7 less 
impairment in shoulder function,9 reduced cytokine release,6,10 
improved delivery of adjuvant chemotherapy,11 lower inci-
dence of complications,12 and economical advantages.13 The 
long-term survival seems to be equivalent to open surgery or 
even better.14 Despite numerous publications addressing lung 
cancer CT screening only a few articles have been published 
addressing the surgical aspects and implications of early 
detection of lung cancer using CT screening.15,16 The relation 
between minimally invasive thoracic surgery and lung cancer 
CT screening has not yet been described in detail.
PATIENTS AND METHODS
Patients
The Danish Lung Cancer Screening trial (DLCST) 
included 4104 smokers and previous smokers enrolled from 
october 1, 2004, to March 31, 2006. Participants were ran-
domized to either screening with five annual low-dose CT 
scans or no screening, as reported previously.17 The study was 
funded in full by the Danish Ministry of Interior and Health, 
and performed in collaboration with the Dutch Belgian 
Randomised Lung Cancer Screening trial (NELSoN).18
Participants were women and men, aged 50 to 70 years, 
without lung cancer related symptoms, and current or previ-
ous smokers with at least a 20 pack-year history. Previous 
smokers had to have quit after the age of 50 years and less 
than 10 years prior to the start of the study. Participants had 
to be able to climb two flights of stairs (36 steps) without 
a pause. Spirometry was performed annually in all partici-
pants and forced expiratory volume in 1 second had to be at 
least 30% of predicted normal at baseline to allow entry into 
the study.
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Exclusion criteria were body weight more than 130 kg, 
previous treatment for lung cancer, breast cancer, malignant 
melanoma, or hypernephroma, in addition to a history of any 
other cancer within 5 years, tuberculosis within 2 years or any 
serious illness with a life expectancy less than 10 years. If 
applicants had had a CT scan of the chest within the last year, 
they were excluded.
The management algorithm for the screen-detected pul-
monary nodules at baseline has been described previously.17 
At incidence screenings, nodules were characterized as new 
or preexisting, as solid, nonsolid, or part-solid in addition to 
the location, size, and shape. Size was assessed by linear mea-
surement and volumetrics. Growth was evaluated by a calcu-
lation of volume doubling time (VDT). Categories of VDT 
were: less than 400 days, 400 to 600 days, and more than 600 
days as also used in the NELSoN trial.18 VDT less 400 days 
was regarded as suspicious of malignancy. In nonsolid nod-
ules both linear growth and change in density (from nonsolid 
to part-solid) was used as criteria of malignancy.19 Participants 
with nodules with a size less than 5 mm continued the planned 
annual CT screening. At baseline, nodules between 5 and 15 
mm were followed with a CT scan after 3 months. If growth 
of more than 25% was detected, the participant was referred to 
diagnostic evaluation by a pulmonologist, as were those with 
nodules larger than 15 mm.17 At the incidence rounds, patients 
with nodules with VDT less than 400 days were referred to the 
pulmonologist as were nonsolid nodules with growth and/or 
change to part-solid lesions.
When a clinical suspicion of lung cancer was made, all 
patients in the control arm followed the formalized Danish 
national guidelines. The guidelines are similar to those 
described by Lim et al.20
The indication for surgical or oncologic intervention 
was decided by a multidisciplinary team of pulmonologists, 
radiologists, a pathologist, an oncologist, and a thoracic sur-
geon in all cases.17 The data were prospectively registered in 
an institutional database.
CT-guided biopsy can be difficult in small nodules. 
When CT-guided biopsy was not feasible, we used VATS 
wedge resection and frozen section as diagnostic tools. In case 
of lung cancer, VATS lobectomy was performed in the same 
procedure.
All patients underwent a pulmonary-function test, bron-
choscopy and, standard dose CT scan with contrast of the chest 
and upper abdomen. The mediastinum was further evaluated 
with endobronchial ultrasound, endo-esophageal ultrasound, 
or mediastinoscopy before pulmonary resection.
Positron emission tomography (PET) was used in partic-
ipants with indeterminate nodules and as a staging procedure 
before surgery. PET and VDT predicted lung cancer indepen-
dently of each other. Combining PET and VDT resulted in a 
sensitivity of 90% and a specificity of 82%.21 Exclusion crite-
ria for VATS lobectomy included tumor size larger than 6 cm, 
suspected chest-wall or diaphragm involvement, and centrally 
located tumors visible by bronchoscopy, possibly requiring 
sleeve resection or pneumonectomy. For patients with severe 
comorbidity, suspected N1 disease, former radiation, or for-
mer thoracic surgery on the same side was not considered to 
be an exclusion criterion.
Surgical Procedures
For open operations a muscle-sparring posterolateral 
thoracotomy was performed. The VATS operations were 
performed using an anterior approach with two ports and a 
5-cm utility incision, described in detail in a recent publica-
tion.22 Patients were positioned in the lateral decubitus after 
double-lumen intubation for lung isolation. Two monitors 
were placed on each side of the table with the surgeon and the 
assistant positioned anterior to the patient. The scrub nurse 
was on the opposite side to the assistant. A 5-cm utility inci-
sion was performed just anterior to the edge of the latissimus 
dorsi muscle in the fourth intercostal space, splitting the ser-
ratus anterior muscle along the direction of its muscle fibers 
without using a rib retractor. A 30°C, 10-mm thoracoscope 
(Endoeye; olympus, Hamburg, Germany) was introduced and 
the thoracic cavity was evaluated with regard to unexpected 
pathology, adhesions, and the level of the diaphragm. Then, 
an additional 10-mm port was placed anterior at the level 
of the diaphragm used for the thoracoscope, and an addi-
tional 15-mm port posterior at the level of the diaphragm. 
Lobectomy was performed in a fashion similar to that of an 
open lobectomy with anatomical dissection of the hilum, but 
strictly based on monitor. The pulmonary vein, the bronchus, 
and the branches from the pulmonary artery were dissected 
individually and divided using an endoscopic-stapling device 
(endoGIA; Covidien plc, Norwalk, CT). The specimen was 
retrieved using an endoscopic bag. Systematic mediastinal 
lymph-node dissection was then performed, removing fatty 
tissue and lymph nodes from stations 2, 3, 4, 7, 8, and 9 on the 
right side and stations 5, 6, 7, 8, and 9 on the left side, accord-
ing to the 7th edition of Tumor, Node, Metastasis (TNM) 
classification in lung cancer.23 In case of conversion, the ante-
rior incision was extended to an anterolateral thoracotomy.
Data Analysis
Data were expressed as number and percentage, mean 
and 95% confidence interval (CI), or median (range) when 
appropriate. Categorial values were analyzed by Fischer’s 
exact test. Mann-Whitney U test was used for comparison of 
continuous variables. P values < 0.05 were considered statis-
tically significant. operative mortality included patients who 
died within 30 days.
Ethical and Legal Approval
The DLCST was approved by the Ethical Committee of 
Copenhagen County on January 31, 2003, and funded in full 
by the Danish Ministry of Health and Prevention on June 23, 
2004. Approval of data management in the trial was obtained 
from the Danish Data Protection Agency on February 11, 
2005. The trial is registered in ClinicalTrials.gov Protocol 
Registration System (identification number NCT00496977).
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RESULTS
By February 1, 2011, i.e., approximately 1 year after the 
last screening scan, the screening arm of the DLCST revealed 
77 suspicious nodules, 68 of which were lung cancer, one was 
a metastasis from a testis cancer, one was a lymphoma, and 
the remaining seven were benign.
Seventeen of the 68 patients with lung cancer had 
advanced disease and were referred for radiochemotherapy. 
The remaining 51 lung cancer patients were eligible for surgi-
cal treatment (Fig. 1). Forty-nine operations were performed 
in 46 patients. Three patients underwent a second operation 
because of a new lung cancer discovered in the observation 
period. Two patients had a synchronous tumor in the other 
lobe on the same side, and it was treated in the same operation 
with a supplemental wedge resection.
Forty-one of 49 operations (84%) for lung cancer were 
performed by VATS (95% CI 70%–93%). Thirty-seven major 
VATS resections were performed, including one segmentec-
tomy and 36 lobectomies. Four patients had a VATS wedge 
resection. In this study, lobectomy was considered the gold 
standard for the treatment of lung cancer, but three patients 
did not wish to have a lobectomy after the initial wedge resec-
tion. one patient had a synchronous tumor in the other lobe 
and two wedge resections were considered the best treatment 
for this patient.
There were only two patients presenting a ground glass 
opacity. Because ground glass opacity is known to be difficult 
to palpate, wide-wedge resection was performed by VATS, 
according to the localization on the CT scan.
Five patients had an open lobectomy. Three of these 
were suitable for VATS lobectomy, but there were no VATS 
surgeons available at the institution at the time. Furthermore, 
two intended VATS lobectomies were converted to open lobec-
tomy. one patient had an open extended pneumonectomy 
because of locally advanced disease (Stage IIIa, T3N1M0).
In total, 58 operations were performed in the 
CT-screening arm, and in seven cases (12%, 95% CI 5%–23%) 
the final histology was benign. All seven patients with a benign 
nodule were treated with a VATS procedure. Six patients had 
a VATS wedge resection and one patient had a VATS lobec-
tomy because of the central location of the nodule. The final 
diagnoses of the benign nodules were two hamartomas, two 
granulomas, and three fibrotic lymph nodes.
By February 1, 2011, 24 patients with lung cancer were 
detected in the control group. Sixteen (67%) of the 24 lung 
cancer cases were advanced disease and were referred for 
radiochemotherapy (Fig. 1). Four (17%) had a VATS lobec-
tomy, two (8%) had open lobectomy, and two (8%) had open 
pneumonectomy. The VATS rate in the control arm is 50%, 
(95% CI 16%–84%). In the CT-screened arm the VATS rate of 
84% is significantly higher (p < 0.05).
Tumor stage of the lung cancers in the CT-screened arm 
and the control arm is shown in Table 1 according to the 7th 
edition of TNM classification in lung cancer.20 Significantly 
more lung cancers were diagnosed in the screening group (68 
FIGURE 1. Design of the Danish CT Lung Cancer Screening trial and treatment of the lung cancer.
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versus 24, p < 0.001) and more were stage I (46 versus 5, p < 
0.001). The number of stage-IV cancers was the same in both 
groups (6 versus 7; p > 0.05).
In the CT-screened arm, the tumor size in the thoraco-
tomy group was 55(8–93) mm expressed as median and range 
as compared to the tumor size in VATS group 13(6–36) mm 
reflecting the selection before surgery. The tumor size of the 
benign or negative nodules was 10(10–38) mm versus 16(6–93) 
mm of the positive nodules, indicating that differentiation 
between benign and malignant disease is difficult in small 
lesions.
Complications to surgery in the CT-screened arm are 
listed in Table 2, and the surgical outcome in the 37 major 
VATS resections are summarized in Table 3. There was no 
30-day mortality for the VATS resections, or for the open 
resections. However, after uneventful open lobectomy for a 
12-mm adenocarcinoma, one patient was readmitted on day 
25 with pneumonia, and he died of myocardial infarction with 
congestive heart failure on day 34.
DISCUSSION
The National Lung Screening trial recently announced 
the initial results of a large-scale trial of screening methods 
to reduce deaths from lung cancer by detecting cancers at 
relatively early stages. In a randomized trial involving more 
than 53,000 current and former heavy smokers, the effects of 
two screening procedures—low-dose helical CT and standard 
chest radiograph—on lung cancer mortality were compared. 
Twenty percent fewer lung cancer deaths were seen among 
those screened with low-dose spiral CT than those screened 
with chest radiograph.1 The findings of this study are expected 
to increase the use of low-dose CT screening.
There are some concerns regarding a more widespread 
use of low-dose CT screening. First, the extent of overdiag-
nosis is an important issue. overdiagnosis bias refers to the 
screening-related detection of indolent or slow-growing 
tumors that would never have progressed to clinical disease 
during a person’s lifetime, and thus would not have been 
diagnosed without screening. In the International Early Lung 
Cancer Action Programme (I ELCAB) a high proportion 
(81%) of bronchio-alveolar carcinoma (BAC) was found in 
stage-Ia adenocarcinomas with a subsequent 5-year survival 
of 100% for pure BAC and 95% for mixed BAC.24
Next is the prevalence of false positive nodules. There 
can be psychological consequences of false positive test results. 
In this study, this has been evaluated by a questionnaire and 
will be published separately.17 The screening regime used in this 
study is based primarily on the reports from the ELCAB25–28 and 
was later agreed upon by the European Union-United States 
Collaborative spiral CT working group under the International 
Association for the Study of Lung Cancer (IASLC). In addition, 
the regime was harmonized with the NELSoN trial18 for pool-
ing of results. Any screening aims at having a low rate of false 
positive findings, but high specificity usually implies low sensi-
tivity with a need for a long follow-up. The frequency of surgi-
cal procedures for benign disease in CT-screening trials varies 
TABLE 1. Lung Cancer Stage, Cumulated Detection Rate, 
and Tumor Size of Lung Cancers in the DLCST
Screening Arm 
N = 68
Control Arm 
N = 24
Lung Cancer Stage
 NSCLC
   Ia 37 3
   Ib 9 2
   IIa 0 0
   IIb 0 2
   IIIa 10 1
   IIIb 3 2
   IV 6 7
 SCLC 
   Limited 1 1
   Extensive 2 6
Cumulated detection rate 3,3% 1,2%
VATS rate 84% 50%
DLCST, Danish Lung Cancer Screening Trial; NSCLC, non–small-cell lung cancer; 
SCLC, small-cell lung cancer; VATS, Video-Assisted Thoracic Surgery.
TABLE 2. Complications to Surgery in the CT Screened Arm 
in the DLCST
Thoracotomy, 
N = 8 (%)
VATS,  
N = 41 (%)
Benign,  
N = 7 (%)
Minor
 Reinsertion of tube 0 1 (2) 0
 Pneumonia 1(13) 1 (2) 0
 Bladder infection 0 1 (2) 0
 Transfusion rate 3(38) 2 (5) 0
 Pleurocentesis 0 2 (5) 0
 Air leak > 7 days 2(25) 8 (20) 1 (14)
 Atrial fibrillation 1(13) 1 (2) 1 (14)
 Recurrent nerve paralysis 1(13) 0 0
Major
 Empyema 1(13) 0 0
 Myocardial infarction 1(13) 0 0
 Reoperation because of bleeding 1(13) 1 (2) 0
 Conversion rate — 2 (5) 0
 30-day mortality 0 0 0
CT, computed tomography; DLCST, Danish Lung Cancer Screening trial.
TABLE 3. Patient Characteristics and Surgical Outcome, 
VATS Major Lung Resections, n = 37 Patients
Sex 18 females/19 males
Age 61 years (52–72 years)
FEV1 2.29 l/min (1.42–3.70 l/min)
operating time 135 min (95–240 min)
Intraoperative bleeding 150 ml (50–1500 ml)
Tube time 4.0 days (1–19 days)
In-hospital stay 5.5 days (2–21 days)
Data expressed as median and range.
VATS, Video-Assisted Thoracic Surgery.
1030 Copyright © 2012 by the International Association for the Study of Lung Cancer
Petersen et al. Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012
from 0% to 33% with an average of 18%.29 In our series, seven 
of 58 operations (12%) were performed where the result was a 
benign lesion at final histology. In other series, many of these 
procedures were performed by a thoracotomy.15,16 All benign 
lesions in our series were performed by VATS, and fortunately 
there were no major complications to these procedures.
The finding of suspicious small nodules creates a diag-
nostic challenge because CT-guided biopsy can be technically 
difficult in lesions smalller than 1 cm. In smaller nodules not 
eligible for CT-guided biopsy, we used a VATS wedge resec-
tion and an intraoperative frozen section in the same procedure 
as diagnostic tools. In case of lung cancer VATS, lobectomy 
was performed during the same procedure. Localizing small 
tumors deep in the lung parenchyma by VATS can be techni-
cally challenging. There are a few tricks that can be helpful 
doing this. Dividing the lower pulmonary ligament or dividing 
the hilar pleura can mobilize the lung to make bidigital palpa-
tion through the anterior utility incision possible. Furthermore, 
opening the fissure may aid in accessing tumors deep in the 
parenchyma, thus facilitating a VATS resection. In case of a 
very central tumor close to great vessels a diagnostic VATS 
lobectomy or VATS segmentectomy can be indicated.
In this study lobectomy was considered the gold stan-
dard for lung cancer patients with sufficient lung function. 
Segmentectomy might be an acceptable alternative in patients 
with a T1a tumor.30 There are two large ongoing randomized 
trials that might add evidence to the question, but it will prob-
ably be 5 to 10 years before the data will be available.31,32
Bearing in mind the risk of overdiagnosis and given the 
nature of screening patients, who differ from an average patient 
in a thoracic surgical department, we find a minimally invasive 
approach of outmost importance in these patients. Although 
there is a lack of randomized controlled trials between open 
lobectomy and VATS lobectomy, there have been reported 
numerous benefits for patients in terms of reduced periopera-
tive pain,5–7 shorter hospital stay,8 more rapid resumption of 
normal daily activities,8 less impairment in pulmonary func-
tion postoperatively,6,7 less impairment in shoulder function,9 
reduced cytokine release,6,10 improved delivery of adjuvant 
chemotherapy,11 lower incidence of complications,12 and eco-
nomical advantages.13 Furthermore, the long-term survival 
seems to be equivalent to open surgery or even better.14
The high percentage of lung resections by VATS (84%) 
and a VATS rate of 100% in the benign lesions in DLCST 
has not been reported previously in the literature.15,16 The 
surgical outcome was good and complications were few. We 
believe that it is of outmost importance for future low-dose 
CT-screening trials to have thoracic surgeons involved in the 
early-detection program, and that thoracic surgeons should 
have a dedicated VATS program. In this trial, the VATS sur-
geons were experienced before enrolling of patients. But there 
is a long learning curve in VATS major lung resections that 
should be taken into account.33,34 Despite expertise in VATS 
surgery, there is still a role for thoracotomy in tumors larger 
than 6 cm, central tumors requiring a bronchial or vascular 
sleeve resection, or in case of chest-wall involvement.
In conclusion, lung cancer screening seems to facilitate 
the use of minimally invasive thoracic surgery in the treatment 
of lung cancer with an 84% VATS rate in the CT-screening arm, 
which is significantly higher than that of the control arm (p < 
0.05). All benign nodules could be removed by VATS without 
major complications. Thus, VATS seems to be a valuable tool in 
the diagnostic work up of screening detected lung cancer; and in 
our view, a basic requirement for a surgical institution involved 
in lung cancer screening is a dedicated VATS program.
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